Related Experiment Videos
Nuclear p53 overexpression in bladder, prostate, and renal carcinomas
Summary
Nuclear p53 overexpression is uncommon in urologic cancers like bladder, prostate, and kidney. However, it moderately correlates with key histopathological and clinical features, offering insights into cancer progression.
Area of Science:
- Urologic oncology
- Molecular pathology
- Cancer biomarkers
Background:
- Investigating nuclear p53 overexpression in transitional cell carcinoma of the bladder, prostate adenocarcinoma, and renal cell carcinoma.
- p53 gene mutations are implicated in various cancers.
Purpose of the Study:
- To assess the prevalence of nuclear p53 overexpression in common urologic malignancies.
- To correlate p53 overexpression with clinical and histopathological characteristics.
Main Methods:
- Immunohistochemical analysis using the D07 monoclonal antibody on 44 bladder, 41 prostate, and 39 renal cell carcinoma specimens.
- Defined p53 overexpression as >= 10% positively stained tumor nuclei.
- Correlated findings with clinical and histopathological data.
Main Results:
- Nuclear p53 overexpression detected in 18.2% of bladder, 12.2% of prostate, and 17.9% of renal cell cancers.
- Significant correlations found between p53 overexpression and tumor grade, vascular invasion, necrosis (bladder), high Gleason score (prostate), and 1-year mortality (renal).
Conclusions:
- Nuclear p53 overexpression is relatively infrequent in urologic malignancies.
- p53 overexpression shows moderate correlation with specific histopathological and clinical features, suggesting potential as a prognostic indicator.